SCHEMBL6888786

SCHEMBL6888786

CCN1CCN(c2ccc(OC)nc2)CC1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 3/20 0.57
CHRNA4 P43681 3/20 0.57
GAA P10253 2/20 0.50
RAD52 P43351 2/20 0.50
MAPT P10636 2/20 0.50
KDM4E B2RXH2 1/20 0.50
GFER P55789 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
OGA O60502 1/20 0.49
CHRNB4 P30926 2/20 0.49
CHRNA3 P32297 2/20 0.49
CHRNA7 P36544 1/20 0.49
TNF P01375 1/20 0.47
DRD2 P14416 1/20 0.45
MLLT1 Q03111 1/20 0.43
PRKDC P78527 1/20 0.42
KDM2B Q8NHM5 1/20 0.42
PDE5A O76074 1/20 0.42
KCNH2 Q12809 1/20 0.42
ADORA2A P29274 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22006244 0.84 GAA (0.46) CHRNB2CHRNA4GAARAD52MAPT
SCHEMBL6884588 0.82 CHRNB2 (0.61) CHRNB2CHRNA4GAAMAPTKDM4E
SCHEMBL20804834 0.81 DRD4 (0.56) CHRNB2CHRNA4MAPTKDM4EGFER
SCHEMBL5257852 0.81 CHRNB2 (0.58) CHRNB2CHRNA4GAARAD52MAPT
SCHEMBL5312452 0.80 CHRNB2 (0.72) CHRNB2CHRNA4MAPTKDM4ESMN1; SMN2
SCHEMBL23126233 0.80 OGA (0.57) CHRNB2CHRNA4MAPTSMN1; SMN2OGA
SCHEMBL8931633 0.79 CHRNB2 (0.58) CHRNB2CHRNA4GAARAD52MAPT
SCHEMBL6889419 0.79 GAA (0.54) GAARAD52MAPTKDM4EGFER
SCHEMBL13012269 0.79 CHRNB2 (0.51) CHRNB2CHRNA4GAAMAPTOGA
SCHEMBL18713087 0.78 TRPV6 (0.57) KDM4ESMN1; SMN2TNFRET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230109839-A1 THERAPEUTIC AGENT FOR TAUOPATHIES Sumitomo Pharma Co., Ltd. (JP) 2023-04-13 US disclosed
EP-2501231-B1 QUINOLIZIDINONE CARBOXAMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS MERCK SHARP & DOHME (US) 2016-12-21 EP disclosed
US-8754220-B2 Quinolizidinone carboxamide M1 receptor positive allosteric modulators MERCK SHARP & DOHME CORP. (US) 2014-06-17 US disclosed
US-8754220-B2 Quinolizidinone carboxamide M1 receptor positive allosteric modulators MERCK SHARP & DOHME CORP. (US) 2014-06-17 US disclosed
US-20120232076-A1 QUINOLIZIDINONE CARBOXAMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS MERCK SHARP & DOHME LLC 2012-09-13 US disclosed
US-20120232076-A1 QUINOLIZIDINONE CARBOXAMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS MERCK SHARP & DOHME LLC 2012-09-13 US disclosed
WO-2011062853-A1 QUINOLIZIDINONE CARBOXAMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS MERCK SHARP & DOHME CORP. (US) 2011-05-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230109839-A1 THERAPEUTIC AGENT FOR TAUOPATHIES MAPT, PSEN1, PSEN2 CHRNB2 162/4885CHRNA4 132/4885GAA 445/4885
US-20120232076-A1 QUINOLIZIDINONE CARBOXAMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS CHRM1, CHRM2, CHRM4 CHRNB2 37/4885CHRNA4 7/4885GAA 1851/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.